Form 8-K - Current report:
SEC Accession No. 0001564590-20-051298
Filing Date
2020-11-05
Accepted
2020-11-05 16:06:06
Documents
13
Period of Report
2020-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K kzr-8k_20201105.htm   iXBRL 8-K 37004
2 EX-99.1 kzr-ex991_6.htm EX-99.1 90129
  Complete submission text file 0001564590-20-051298.txt   271077

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kzr-20201105.xsd EX-101.SCH 5793
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kzr-20201105_lab.xml EX-101.LAB 20220
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kzr-20201105_pre.xml EX-101.PRE 12097
6 EXTRACTED XBRL INSTANCE DOCUMENT kzr-8k_20201105_htm.xml XML 3685
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 201290423
SIC: 2834 Pharmaceutical Preparations